TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from ImmuPharma ( (GB:IMM) ).
ImmuPharma has filed a new patent application for its lead asset P140, the world’s first ‘Immunormalizer,’ which offers a novel diagnostic test and precision treatment for autoimmune diseases. This patent provides the potential for 20 years of commercial exclusivity and positions ImmuPharma as a leader in precision medicine for autoimmune diseases. The new approach targets a subpopulation of patients with Type M immune disorder, offering a safer and more effective alternative to current treatments. The diagnostic test is expected to improve patient selection for clinical trials, enhance the probability of regulatory approval, and create significant commercial opportunities in the autoimmune diagnostics market.
More about ImmuPharma
ImmuPharma PLC is a specialty biopharmaceutical company that focuses on discovering and developing peptide-based therapeutics. The company’s portfolio includes novel peptide therapeutics aimed at treating autoimmune diseases and anti-infectives.
Average Trading Volume: 2,184,678
Technical Sentiment Signal: Sell
Current Market Cap: £11.12M
Find detailed analytics on IMM stock on TipRanks’ Stock Analysis page.